Evidence map›Paper›PMID 20450868›Full record

ArticleVaccine2010

Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins.

Govind Ragupathi, Payal Damani, Kai Deng, Michelle M Adams, Jianfeng Hang, Constantine George, Philip O Livingston, David Y Gin

Abstract readComparative Study
In one paragraph

Article in Vaccine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Chemical science · 2016
    Article
  8. Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2016
    Review
  9. New vaccines against influenza virus.Clinical and experimental vaccine research · 2014
    Review
  10. Synthesis of QS-21-based immunoadjuvants.The Journal of organic chemistry · 2013
    Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Govind RagupathiLaboratory of Tumor Vaccinology, Melanoma and Sarcoma Service, Department of Medicine, 1275 York Avenue, New York, NY 10065, USA. ragupatg@mskcc.org
Payal Damani
Kai Deng
Michelle M Adams
Jianfeng Hang
Constantine George
Philip O Livingston
David Y Gin
Memorial Sloan Kettering Cancer Center · USNorthern California Melanoma Center · US

Funding

The Molecular Genetics of MUC16P01CA052477 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SOSLOW, ROBERT A · 1991 to 2009
$15.7M
Regulation by the Immune Response to Vaccines by BotanicalsP50AT002779 · NCCIH · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI LEUNG, PING CHUNG · 2005 to 2009
$7.2M
SYNTHESIS OF CARBOHYDRATE IMMUNOSTIMULATING AGENTSR01GM058833 · NIGMS · UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN · PI TAN, DEREK S · 1999 to 2013
$5.4M
NCCIH NIH HHS P50 AT002779NCI NIH HHS P01 CA052477NCI NIH HHS P01 CA 52477NIGMS NIH HHS R01 GM058833
6 · The paper itself

Abstract

The saponin fraction QS-21 from Quillaja saponaria has been demonstrated to be a potent immunological adjuvant when mixed with keyhole limpet hemocyanin conjugate vaccines, as well as with other classes of subunit antigen vaccines. QS-21 adjuvant is composed of two isomers that include the apiose and xylose forms in a ratio of 65:35, respectively. The chemical syntheses of these two isomers in pure form have recently been disclosed. Herein we describe detailed in vivo immunological evaluations of these synthetic QS-21 isomeric constituents, employing the GD3-KLH melanoma antigen. With this vaccine construct, high antibody titers against GD3 ganglioside and KLH were elicited when GD3-KLH was co-administered with adjuvant, either as the individual separate synthetic QS-21 isomers (SQS-21-Api or SQS-21-Xyl), or as its reconstituted 65:35 isomeric mixture (SQS-21). These antibody titer levels were comparable to that elicited by vaccinations employing naturally derived QS-21 (PQS-21). Moreover, toxicities of the synthetic saponin adjuvants were also found to be comparable to that of naturally derived PQS-21. These findings demonstrate unequivocally that the adjuvant activity of QS-21 resides in these two principal isomeric forms, and not in trace contaminants within the natural extracts. This lays the foundation for future exploration of structure-function correlations to enable the discovery of novel saponins with increased potency, enhanced stability, and attenuated toxicity.

Indexed as

Adjuvants, ImmunologicAnimalsAntibody FormationCancer VaccinesDrug Evaluation, PreclinicalFemaleGangliosidesHemocyaninsMelanomaMiceMice, Inbred C57BLMolecular StructureSaponinsAdjuvants, ImmunologicCancer Vaccinesganglioside, GD3GangliosidesHemocyaninskeyhole-limpet hemocyaninsaponin QA-21V1Saponins

Identifiers

PMID20450868
PMCPMC2882175
OpenAlexW2021318343

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.